We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Performance of Chagas Disease Genotyping Assay Evaluated

By LabMedica International staff writers
Posted on 07 Apr 2017
Chagas disease remains a significant public health issue infecting six to seven million people worldwide. More...
The factors influencing the clinical heterogeneity of Chagas disease have not been elucidated, although it has been suggested that different clinical outcome may be associated with the genetic diversity of Trypanosoma cruzi isolates.

Differences in therapeutic response of distinct T. cruzi genotypes have been also reported. Typing strategies for genotype-specific diagnosis of Chagas disease to identify the T. cruzi discrete typing units (DTU) have already been developed, including biochemical and molecular methods, however the techniques have limitations.

Scientists at the Federal University of Ouro Preto used standard T. cruzi strains, representative of three major genotypes involved in the domestic cycle of Chagas disease in Brazil, to setup the TcI/TcVI/TcII Chagas-Flow ATE-IgG2a methodology for the serodiagnosis of T. cruzi infection. The team maintained the strains in mice and the infection was confirmed in all T. cruzi-infected mice, by positivity at fresh blood examination performed at day 7, 10 or 15 post-infection. The serum samples used for the TcI/TcVI/TcII Chagas-Flow ATE-IgG2a serology were prepared from whole blood samples collected by ocular plexus puncture.

The amastigote/trypomastigote/epimastigote forms of TcI, TcVI and TcII T. cruzi genotypes were obtained and the TcI/TcVI/TcII Chagas-Flow ATE-IgG2a serodiagnosis was performed. Flow cytometric data was acquired with a FACSCanto flow cytometer. Following the selection of target-antigens, one-dimensional histograms were employed to quantify the genotype-specific anti-T. cruzi IgG2a reactivity, based on the positivity limit set based on the internal control. The results were expressed as percentage of positive fluorescent parasites (PPFP) for each tested sample dilution.

The data acquired demonstrated that “α-TcII-TRYPO/1:500, cut-off/PPFP = 20%” presented an excellent performance for universal diagnosis of T. cruzi infection. The combined set of attributes “α-TcI-TRYPO/1:4,000, cut-off/PPFP = 50%”, “α-TcII-AMA/1:1,000, cut-off/PPFP = 40%” and “α-TcVI-EPI/1:1,000, cut-off/PPFP = 45%” showed good performance to segregate infections with TcI/Colombiana, TcVI/CL or TcII/Y strain. Overall, hosts infected with TcI/Colombiana and TcII/Y strains displayed opposite patterns of reactivity with “α-TcI TRYPO” and “α-TcII AMA”.

The authors concluded that the method presented a good performance for genotype-specific diagnosis, with global accuracy of 69% when the population/prototype scenario include TcI, TcVI and TcII infections and 94% when comprise only TcI and TcII infections. The method providing a feasible tool to classify serum samples from hosts infected with distinct T. cruzi genotypes, supporting the potential of this method for universal and genotype-specific diagnosis of T. cruzi infection. The study was published on March 23, 2017, in the journal Public Library of Science Neglected Tropical Diseases.


Gold Member
Cardiovascular Risk Test
Metabolic Syndrome Array I & II
Collection and Transport System
PurSafe Plus®
Clinical Chemistry System
P780
Sample Transportation System
Tempus1800 Necto
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Industry

view channel
Image: The collaboration aims to improve access to Hb variant testing with the Gazelle POC diagnostic platform (Photo courtesy of Hemex Health)

Terumo BCT and Hemex Health Collaborate to Improve Access to Testing for Hemoglobin Disorders

Millions of people worldwide living with sickle cell disease and other hemoglobin disorders experience delayed diagnosis and limited access to effective care, particularly in regions where testing is scarce.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.